2026-06-01T08:54:13Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/88342024-03-16T01:05:17Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220
Chaudhuri, K. Ray
9c6dffc7-c13f-407e-b690-89052e59d909
600
Kovács, Norbert
149d8665-cabe-4e26-8309-242f580acc9c
600
Pontieri, Francesco E.
0e19bd2c-02a2-4948-84bf-c05c0f7c94c8
600
Aldred, Jason
3efc0f48-3958-4907-ae8f-c3b0f11b415f
600
Bourgeois, Paul
b487d6bc-0f84-4b8f-818a-2240c88e3a5f
600
Davis, Thomas L.
e3f0ce6d-083c-4b71-a06a-59a170e7e077
600
Cubo Delgado, Esther
131
600
0000-0003-0018-1182
Anca-Herschkovitsch, Marieta
e1a4479e-6471-49b3-92d2-17279109f9d7
600
Iansek, Robert
c3e67ffe-d7fd-4cc4-8e0b-713fd18e398a
600
Siddiqui, Mustafa S.
1ac8fffa-db1e-4ee2-8a6d-0461cd702bcc
600
Simu, Mihaela
c804cd12-7b9d-499a-823a-f929b9eb69f2
600
Bergmann, Lars
39398a25-ebc2-4008-b8c7-be0c8426ad38
600
Ballina, Mayra
7b031ac3-11e3-42b1-b7be-ef6d5975de72
600
Kukreja, Pavnit
310f6280-4048-40e8-a3ad-51110ca1805b
600
Ladhani, Omar
01fe1d10-6fc9-4839-8cf8-1a4c0cd60498
600
Jia, Jia
5dd77c45-28a9-44e9-9f69-64cf65806562
600
Standaert, David G.
6da922f3-858b-4e9f-9899-3e00594a5650
600
2024-03-15T09:40:13Z
2024-03-15T09:40:13Z
2023-07
1877-7171
http://hdl.handle.net/10259/8834
10.3233/JPD-225105
1877-718X
Background:
Levodopa-carbidopa intestinal gel (LCIG) improves motor and non-motor symptoms in patients with advanced Parkinson’s disease (aPD).
Objective:
To present the final 36-month efficacy and safety results from DUOGLOBE (DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease – a GLobal OBservational Study Evaluating Long-Term Effectiveness; NCT02611713).
Methods:
DUOGLOBE was an international, prospective, long-term, real-world, observational study of patients with aPD initiating LCIG in routine clinical care. The primary endpoint was change in patient-reported “Off” time to Month 36. Safety was assessed by monitoring serious adverse events (SAEs).
Results:
Significant improvements in “Off” time were maintained over 3 years (mean [SD]: –3.3 hours [3.7]; p < 0.001). There were significant improvements to Month 36 in total scores of the Unified Dyskinesia Rating Scale (–5.9 [23.7]; p = 0.044), Non-Motor Symptoms Scale (–14.3 [40.5]; p = 0.002), Parkinson’s Disease Sleep Scale-2 (–5.8 [12.9]; p < 0.001), and Epworth Sleepiness Scale (–1.8 [6.0]; p = 0.008). Health-related quality of life and caregiver burden significantly improved through Months 24 and 30, respectively (Month 24, 8-item Parkinson’s Disease Questionnaire Summary Index, –6.0 [22.5]; p = 0.006; Month 30, Modified Caregiver Strain Index, –2.3 [7.6]; p = 0.026). Safety was consistent with the well-established LCIG profile (SAEs: 54.9% of patients; discontinuations: 54.4%; discontinuations due to an adverse event: 27.2%). Of 106 study discontinuations, 32 patients (30.2%) continued LCIG outside the study.
Conclusion:
DUOGLOBE demonstrates real-world, long-term, reductions in motor and non-motor symptoms in patients with aPD treated with LCIG.
application/pdf
eng
IOS Press
Journal of Parkinson's Disease. 2023, V. 13, n. 5, p. 769-783
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd225105
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
DUOGLOBE
Parkinson’s disease
Levodopa-carbidopa intestinal gel
Dyskinesia
Real-world data
Sistema nervioso-Enfermedades
Medicina
Neurología
Nervous system-Diseases
Medicine
Neurology
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Journal of Parkinson's Disease
13
5
769
783
THUMBNAIL
Chaudhuri-jpd_2023.pdf.jpg
Chaudhuri-jpd_2023.pdf.jpg
IM Thumbnail
image/jpeg
4290
https://riubu.ubu.es/bitstream/10259/8834/4/Chaudhuri-jpd_2023.pdf.jpg
1b20695f897939969757b2fe30cd94b7
MD5
4
LICENSE
license.txt
license.txt
text/plain; charset=utf-8
999
https://riubu.ubu.es/bitstream/10259/8834/3/license.txt
b295bcbce42e2caabeb0c623d3860c06
MD5
3
CC-LICENSE
license_rdf
license_rdf
application/rdf+xml; charset=utf-8
908
https://riubu.ubu.es/bitstream/10259/8834/2/license_rdf
0175ea4a2d4caec4bbcc37e300941108
MD5
2
ORIGINAL
Chaudhuri-jpd_2023.pdf
Chaudhuri-jpd_2023.pdf
application/pdf
643399
https://riubu.ubu.es/bitstream/10259/8834/1/Chaudhuri-jpd_2023.pdf
f551fb6b8e11d310b7bfc4e7ca9c074d
MD5
1
10259/8834
oai:riubu.ubu.es:10259/8834
2024-03-16 02:05:17.556
Repositorio Institucional de la Universidad de Burgos
bubrep@ubu.es
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